Navigation Links
InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
Date:5/18/2009

OXFORD, England, May 18 /PRNewswire/ -- PharmaVentures Ltd, announced today that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD). The engagement will utilise PharmaVentures' transactions experience in the healthcare and investment business sectors.

Kappaproct, approved for Orphan Drug Designation in Europe, has recently successfully concluded its third clinical phase II trial for the treatment of Inflammatory Bowel Disease patients. Due to the highly positive interim results at both one and four weeks after dosing, this trial, which included 34 patients and was conducted as a multi-center study in Sweden and Russia, was concluded early. Kappaproct showed the same excellent safety profile as seen in previous trials.

Kappaproct is currently approved for clinical developmental use as a rectal, single-dose administration. Qualification of the compound for other routes of administration and multiple dosing is underway through an extended toxicology program.

Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures is very pleased to be involved in bringing this groundbreaking technology to the market. InDex are leaders in the field of immunomodulation via Toll Like Receptors."

InDex will be presenting Phase II data at BIO on Wednesday 20th May. See also InDex's Press Release released today: http://www.indexpharmab.com/images/pdf/kappaproctmay2009.pdf

Visit PharmaVentures during BIO at booths 4209 & 4211 for further information on this and other licensing opportunities.

    For enquiries about this opportunity, please contact:
    Dr Adrian Dawkes
    Managing Consultant
    PharmaVentures
    adrian.dawkes@pharmaventures.com
    +44 (0) 1865 784 193

Notes to Editors:

A leading results driven organisation, PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored consulting and transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals range of intelligence products which include analysis tools and reports.

For further information please contact:

    Fiona Bishop
    PharmaVentures
    +44 (0) 1865 784 187
    fiona.bishop@pharmaventures.com

InDex Pharmaceuticals AB ("InDex") is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its DIMS platform (DNA-based immunomodulatory sequence). DIMS drugs are developed to treat diseases within a variety of therapeutic areas, including inflammation and cancer. InDex has several proprietary DIMS compounds in various stages of development, including Kappaproct, for the treatment of steroid resistant/dependent ulcerative colitis.

    Svante Rasmuson, CEO
    Phone: +46 (0)8 50 88 47 31
    Mobile: +46 (0)708 63 93 31
    E-Mail: svante.rasmuson@indexpharmab.com

    Oliver von Stein, CSO
    Phone: +46 (0)8 50 88 47 32
    Mobile: +46 (0)708 93 33 75
    E-Mail: oliver.stein@indexpharmab.com

www.indexpharmab.com


'/>"/>
SOURCE PharmaVentures
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Standard & Poors Announces Changes to U.S. Index
2. Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment
3. Cocaine Use Among U.S. Workers Declines Sharply in 2008, According to Quest Diagnostics Drug Testing Index(TM)
4. Chindex International, Inc. Announces May Conference Participation
5. ICW Master Patient Index Passes HITSP Certification and IHE Tests
6. SXC Health Solutions Added to S&P/TSX Composite Index
7. HCD Research and Muhlenberg College Will Use an Index to Monitor Physicians and Consumers Perceptions of Health Care Reform
8. MIB Life Index Reports North American Life Insurance Activity up 1.1% in February
9. Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture Investment Conference 2009
10. Molecular Oncology accepted into Thomson Reuters index
11. Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
Breaking Medicine Technology: